Microdosing GLP-1: The Trend, the Reality, and What the Data Shows
Microdosing GLP-1 means taking sub-therapeutic doses (e.g., semaglutide 0.25–0.5 mg) for maintenance or "optimization." It can be reasonable as a maintenance dose after weight loss. The aesthetic-microdosing trend in non-overweight patients is poorly studied and has real risks. Talk to a real doctor, not a wellness influencer.
"Microdosing GLP-1" is the latest term for using sub-therapeutic doses of semaglutide or tirzepatide. It exists on a spectrum from medically reasonable (low maintenance dose after weight loss) to clinically questionable (optimization in already-thin patients).
What microdosing actually means
Sub-therapeutic doses. For semaglutide that typically means:
- 0.25 mg or 0.5 mg weekly (vs therapeutic 1.0–2.4 mg)
For tirzepatide:
- 2.5 mg or 5 mg weekly (vs therapeutic 7.5–15 mg)
The trend has been driven by:
- Patients who finished weight loss and want to maintain
- Patients who didn't respond well to standard doses and stayed at lower
- Wellness influencers promoting "metabolic optimization"
- Non-overweight patients seeking aesthetic loss
When microdosing is medically reasonable
1. Maintenance after weight loss. Many patients can sustain weight loss on a lower dose than they used to lose it. This is established clinical practice.
2. Tapering off. Stepping down through lower doses before stopping reduces rebound risk. Microdoses are a step in this taper.
3. Patients who only tolerate low doses. Some patients can't titrate up due to side effects. Staying at a low dose with modest results is better than no treatment.
4. Type 2 diabetes maintenance. Some diabetic patients maintain glycemic control on low doses indefinitely.
5. Re-initiating after a break. Restarting at a low dose to manage side-effect tolerance.
When microdosing is questionable
Aesthetic use in non-overweight patients. The "I want to lose 10 vanity pounds" framing. Issues:
- Risk-benefit math doesn't favor a medication with real side effects (pancreatitis, gallbladder, thyroid warnings) for cosmetic use
- Lean mass loss in already-thin patients is significant
- Compounded products often used here, with quality issues
- Off-label prescribing without proper medical evaluation
- Insurance won't cover; cash-pay or compounded options dominate
"Optimization" framing without metabolic disease. Influencers promoting GLP-1 for "longevity" or "biohacking" are running ahead of the data. Most of the cardiovascular and metabolic benefits in trials were in patients with elevated weight or diabetes. Extrapolation to lean patients is speculative.
What the data actually shows for microdoses
The pivotal trials were done at therapeutic doses. Microdose data is mostly:
- Subgroup analyses from the lower-dose arms
- Real-world clinical experience
- Maintenance-phase data from extension studies
- Not systematic randomized trials
What we can say:
- Maintenance: low doses (0.25–0.5 mg semaglutide, 2.5–5 mg tirzepatide) often successfully prevent rebound
- Modest active loss: low doses produce modest weight loss (~5%) on their own
- Side effects: usually milder than at therapeutic doses
- Cost: lower
What we don't have great data on:
- Long-term safety in lean patients
- "Metabolic optimization" claims
- Specific dosing protocols outside of trials
The risks of low-supervision microdosing
The biggest concern with the trend isn't the dose — it's the channel:
- Telehealth services prescribing without proper evaluation
- Compounded products of variable quality
- Wellness influencers giving medical-sounding advice
- Patients self-titrating without clinical guidance
- Skipping appropriate workup (thyroid history, pancreatitis history, etc.)
A microdose from a real doctor with real medical evaluation is fine. A microdose ordered from an Instagram ad without bloodwork or evaluation is not.
What to do if you're considering microdosing
1. See a real doctor. Not a "weight loss telehealth" portal that prescribes everyone everything.
2. Get baseline labs. TSH, lipid panel, CMP, CBC, HbA1c, fasting insulin.
3. Document your goals. "Maintain weight after 30-lb loss" is reasonable. "Lose 8 vanity pounds" is harder to justify medically.
4. Use brand-name product. Compounded variability is a bigger problem at lower doses where small variations matter more proportionally.
5. Track outcomes. Weight, body composition, labs over time. Be willing to stop if it isn't producing benefit.
A reasonable framework
For most patients, a useful framework:
- BMI ≥30 (or ≥27 with comorbidity): Standard dosing, with maintenance dose tapering after goal reached
- BMI 25–30 with metabolic concerns: Standard dosing reasonable; maintenance microdose appropriate after goal
- BMI 22–25, healthy, "vanity" weight loss: Genuine question of whether GLP-1 is appropriate at all; if used, microdose with full medical evaluation
- BMI <22: Not appropriate for weight loss use under current understanding
Bottom line
Microdosing GLP-1 has legitimate clinical uses (maintenance, tapering, intolerance to higher doses). The aesthetic-optimization trend in non-overweight patients is poorly supported by data and often happens through low-supervision channels. If you're considering it, see a real doctor, use brand-name product, and be honest about whether the indication justifies the medication.